We are a consortium of companies who work together to find, fund and develop bioscience discoveries into life-changing medical innovations – and take them to the people who need them most.
Our scientific team identifies scientific discoveries from laboratories all over the world that have the potential to have life-changing impact.
Our corporate advisory and investment banking teams work together to translate scientific milestones into value creation events, creating financial instruments and corporate structures that activate commercial value.
Our commercialization team partners with healthcare providers and unlocks regulatory pathways to take the discovery to the people who need it.
2021
OncoTEX Inc. announced manufacturing agreement with Sterling Pharma Solutions to commence production of OxaliTEX.
GBS Inc. and Wyss Institute for Biologically Inspired Engineering commence clinical study using COVID-19 samples to verify biosensor strip.
OxaliTEX granted Australian patent approval.
The iQ Group Global celebrates 10-years of innovation.
GBS Inc. enters sponsored research agreement with John Hopkins Bloomberg School of Public Health to accelerate development of saliva-based diagnostic tests.
GBS Inc. and Wyss Institute for Biologically Inspired Engineering commence clinical study using COVID-19 samples to verify biosensor strip.
OxaliTEX granted Australian patent approval.
The iQ Group Global celebrates 10-years of innovation.
GBS Inc. enters sponsored research agreement with John Hopkins Bloomberg School of Public Health to accelerate development of saliva-based diagnostic tests.
2020
GBS Inc. Nasdaq IPO
Harvard’s Wyss Institute licenses its eRapid technology to The iQ Group Global.
Partnered with Harvard University’s Wyss Institute for Biologically Inspired Engineering for real-time, printable COVID-19 test.
Recognised as one of Australia’s Most Innovative Companies for second consecutive year.
FDA engagement commences for Saliva Glucose Biosensor in the US.
OncoTEX team publishes landmark OxaliTEX preclinical trial findings in Proceedings of the National Academy of Sciences (PNAS).
iQNovate Ltd (NSX:IQN) name change to The iQ Group Global Ltd (NSX:IQG).
Harvard’s Wyss Institute licenses its eRapid technology to The iQ Group Global.
Partnered with Harvard University’s Wyss Institute for Biologically Inspired Engineering for real-time, printable COVID-19 test.
Recognised as one of Australia’s Most Innovative Companies for second consecutive year.
FDA engagement commences for Saliva Glucose Biosensor in the US.
OncoTEX team publishes landmark OxaliTEX preclinical trial findings in Proceedings of the National Academy of Sciences (PNAS).
iQNovate Ltd (NSX:IQN) name change to The iQ Group Global Ltd (NSX:IQG).
2019
The iQ Group Global acquires TEX Core, an oncology drug platform.
Recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine.
FarmaForce wins Sales Team of the Year at PRIME Awards for the third time.
Capital Labs raises more than $828,000 for healthcare startup.
Recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine.
FarmaForce wins Sales Team of the Year at PRIME Awards for the third time.
Capital Labs raises more than $828,000 for healthcare startup.
2018
China patent granted for Saliva Glucose Biosensor.
FarmaForce wins Sales Team of the Year at PRIME Awards for the second time.
FarmaForce wins Sales Team of the Year at PRIME Awards for the second time.
2017
US patent granted for Saliva Glucose Biosensor.
2016
The iQ Group Global accelerated the development of the Saliva Glucose Biosensor.
iQ Capital incorporated in the USA.
Series 8 Fund launched.
FarmaForce wins Sales Team of the Year at PRIME Awards.
iQ Capital incorporated in the USA.
Series 8 Fund launched.
FarmaForce wins Sales Team of the Year at PRIME Awards.
2015
2014
Inception of CRC and FarmaForce.
2012
iQnovate commences trading in the USA.
2010
Inception of iQnovate
Our Collaborators
